Tie2 angiopoietin receptor (Tie2)

The Tie2 angiopoietin receptor, also known as TEK or Tyrosine-protein kinase receptor Tie‑2, is an endothelial cell-specific receptor tyrosine kinase, primarily expressed on blood and lymphatic vessel endothelium. It binds members of the angiopoietin family of growth factors, including Angiopoietin‑1 (Ang1) as an agonist that promotes vessel stability, and Angiopoietin‑2 (Ang2) which acts as a context-dependent antagonist/agonist involved in destabilization during inflammation or hypoxia. The activation state of Tie2 regulates key processes such as vascular maturation, remodeling, maintenance of endothelial barrier integrity, postnatal angiogenesis, inflammation response modulation, tumor neovascularization, atherosclerosis development, sepsis-induced vascular leakage, among others. The orphan coreceptor Tie1 modulates these responses through heterodimerization with Tie2 at cell junctions.[1][3][4][5] Structurally, the extracellular domain contains immunoglobulin-like domains responsible for ligand binding; activation involves dimerization/clustering upon ligand engagement leading to autophosphorylation and signal propagation inside cells.[4] Due to its central role in pathological neovascularization—especially cancer—and cardiovascular diseases involving abnormal vasculature function or integrity loss—Tie2 is considered a high-value therapeutic target for drug development efforts aimed at modulating blood vessel behavior.[4]

Other names

Tunica intima endothelial kinase 2 (Tek)Tyrosine-protein kinase receptor Tie-2Angiopoietin receptor Tie2TEK receptor tyrosine kinaseTIE2

Drugs targeting this molecule typically act by: – Agonizing or antagonizing the interaction between Tie2 and its ligands (angiopoietins), thereby modulating downstream signaling pathways that control blood vessel stability, permeability, and growth.[1][3] – Inhibiting pathological angiogenesis by blocking ligand binding or downstream phosphorylation events.